Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer

Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari, Richard D. Kim, Ray McDermott, Dominic T. Moore, William Zamboni, William Grogan, Allen Lee Cohn, Tanios S. Bekaii-Saab, Gregory Leonard, Theresa Ryan, Olugbenga O. Olowokure, Nishan H. Fernando, John McCaffrey, Bassel F. El-Rayes, Anne M. Horgan, Gary Bradley SherrillGeorge Hosni Yacoub, Bert H. O'Neil

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences